[EN] PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS [FR] CARBOXYLATES DE PIPÉRIDIN-1-YLE ET D'AZÉPIN-1-YLE À TITRE D'AGONISTES DU RÉCEPTEUR MUSCARINIQUE M4
[EN] PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS [FR] CARBOXYLATES DE PIPÉRIDIN-1-YLE ET D'AZÉPIN-1-YLE À TITRE D'AGONISTES DU RÉCEPTEUR MUSCARINIQUE M4
PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS
申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
公开号:US20150376179A1
公开(公告)日:2015-12-31
The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R
2
and R
3
are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.
Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
申请人:Heptares Therapeutics Limited
公开号:US10030012B2
公开(公告)日:2018-07-24
The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.
PIPERIDIN-1-YL AND AZEPIN-1-YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS
申请人:Heptares Therapeutics Limited
公开号:EP2953940B1
公开(公告)日:2018-08-22
US9593106B2
申请人:——
公开号:US9593106B2
公开(公告)日:2017-03-14
[EN] PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS<br/>[FR] CARBOXYLATES DE PIPÉRIDIN-1-YLE ET D'AZÉPIN-1-YLE À TITRE D'AGONISTES DU RÉCEPTEUR MUSCARINIQUE M4
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2014122474A1
公开(公告)日:2014-08-14
The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.